GSK
885 hedge funds and large institutions have $12B invested in GSK in 2024 Q2 according to their latest regulatory filings, with 77 funds opening new positions, 309 increasing their positions, 304 reducing their positions, and 87 closing their positions.
58% more call options, than puts
Call options by funds: $172M | Put options by funds: $109M
2% more repeat investments, than reductions
Existing positions increased: 309 | Existing positions reduced: 304
0.01% more ownership
Funds ownership: 7.51% → 7.52% (+0.01%)
3% less funds holding
Funds holding: 911 → 885 (-26)
10% less capital invested
Capital invested by funds: $13.3B → $12B (-$1.34B)
11% less first-time investments, than exits
New positions opened: 77 | Existing positions closed: 87
29% less funds holding in top 10
Funds holding in top 10: 14 → 10 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$92.7M |
| 2 |
LP
LMR Partners
London,
United Kingdom
|
+$88.3M |
| 3 |
Fisher Asset Management
Camas,
Washington
|
+$85.7M |
| 4 |
Primecap Management
Pasadena,
California
|
+$74.6M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$73.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Holocene Advisors
New York
|
-$127M |
| 2 |
Morgan Stanley
New York
|
-$99.4M |
| 3 |
Citigroup
New York
|
-$73.8M |
| 4 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$70.8M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$55.9M |
GSK Hedge Fund Activity: Q2 2024 in Review
885 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q2 2024, worth a combined $12B — down 10% from $13.3B a quarter earlier.
Sellers outnumbered buyers: 87 funds closed out of GSK and 77 opened new positions — a net loss of 10 holders — while 304 trimmed existing stakes and 309 added.
The largest buyer was Fidelity Investments, adding an estimated $92.7M. The largest seller was Holocene Advisors, cutting an estimated $127M.
- 885 institutional investors held GSK (GSK) as of Q2 2024, down from 911 in Q1 2024.
- Funds reported $12B of GSK stock for Q2 2024, down 10% quarter-over-quarter.
- 77 funds opened new GSK positions in Q2 2024 and 87 closed out, a net change of -10 holders.
- The largest GSK buyer in Q2 2024 was Fidelity Investments, an estimated $92.7M added.
- The largest GSK seller in Q2 2024 was Holocene Advisors, an estimated $127M sold.
Based on aggregated 13F filings for Q2 2024.